German Cancer Consortium (DKTK) - A national consortium for translational cancer research.
Germany
multisite cooperation
personalized oncology
research consortium
translational cancer research
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
16
11
2018
accepted:
26
11
2018
pubmed:
19
12
2018
medline:
30
11
2019
entrez:
19
12
2018
Statut:
ppublish
Résumé
The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.
Identifiants
pubmed: 30561127
doi: 10.1002/1878-0261.12430
pmc: PMC6396349
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-542Informations de copyright
© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Mol Oncol. 2017 Dec;11(12):1661-1672
pubmed: 29024497
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Mol Oncol. 2019 Mar;13(3):521-527
pubmed: 30657633
Eur J Cancer. 2016 Sep;65:91-101
pubmed: 27479119
Neuro Oncol. 2018 Mar 27;20(4):445-456
pubmed: 29194500
Neuro Oncol. 2019 Jan 1;21(1):95-105
pubmed: 30277538
Neuro Oncol. 2018 May 18;20(6):826-837
pubmed: 29165638
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Cancer. 2017 Sep 1;141(5):877-886
pubmed: 28597939